Arrowhead Pharmaceuticals, Inc. $ARWR Stock Position Lowered by Privium Fund Management B.V.

Key Points

• Institutional investor Privium Fund Management B.V. cut its stake in Arrowhead Pharmaceuticals by 16.0% in Q4 to 398,204 shares, representing about $26.44 million and making ARWR its sixth-largest holding.
• Company insiders have been selling: over the last 90 days 33,095 shares were sold (including James C. Hamilton's 10,000-share sale at $75 and CFO Daniel Apel's 13,095-share sale at $71.35), transactions executed under pre-arranged Rule 10b5-1 plans.
• Analyst sentiment is broadly positive with a consensus rating of “Moderate Buy” and an average target of $84.20; ARWR trades near $74.93 with a market cap of about $10.49 billion.

Privium Fund Management B.V. cut its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 16.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 398,204 shares of the biotechnology company's stock after selling 75,747 shares during the period. Arrowhead Pharmaceuticals comprises about 4.9% of Privium Fund Management B.V.'s holdings, making the stock its 6th largest position. Privium Fund Management B.V. owned about 0.28% of Arrowhead Pharmaceuticals worth $26,437,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. iSAM Funds UK Ltd purchased a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter worth about $29,000. First Horizon Corp purchased a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter worth about $32,000. WPG Advisers LLC boosted its position in shares of Arrowhead Pharmaceuticals by 384.8% in the 4th quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company's stock worth $36,000 after buying an additional 431 shares in the last quarter. Federated Hermes Inc. purchased a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter worth about $52,000. Finally, Smartleaf Asset Management LLC boosted its position in shares of Arrowhead Pharmaceuticals by 2,186.5% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,692 shares of the biotechnology company's stock worth $57,000 after buying an additional 1,618 shares in the last quarter. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 10,000 shares of the company's stock in a transaction dated Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total value of $750,000.00. Following the transaction, the insider directly owned 226,958 shares in the company, valued at approximately $17,021,850. This represents a 4.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of the company's stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $71.35, for a total transaction of $934,328.25. Following the transaction, the chief financial officer directly owned 162,905 shares of the company's stock, valued at approximately $11,623,271.75. This represents a 7.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 33,095 shares of company stock worth $2,326,228. 3.60% of the stock is owned by insiders.

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR opened at $74.93 on Wednesday. The firm has a market cap of $10.49 billion, a price-to-earnings ratio of 48.97 and a beta of 1.28. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.29. The company's 50-day moving average is $63.70 and its two-hundred day moving average is $59.78. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $12.44 and a 12-month high of $77.90.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.60 by ($0.38). The firm had revenue of $264.03 million during the quarter, compared to analysts' expectations of $225.66 million. Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. Arrowhead Pharmaceuticals's revenue for the quarter was up 10461.3% on a year-over-year basis. During the same quarter last year, the company posted ($1.39) earnings per share. Research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3.37 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on ARWR shares. HC Wainwright reiterated a "buy" rating and issued a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, March 25th. Morgan Stanley upgraded shares of Arrowhead Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $78.00 to $100.00 in a research report on Tuesday, April 21st. B. Riley Financial boosted their price objective on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a "buy" rating in a research report on Thursday, January 22nd. Chardan Capital boosted their target price on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a "buy" rating in a research note on Wednesday, January 7th. Finally, Weiss Ratings upgraded shares of Arrowhead Pharmaceuticals from a "sell (d-)" rating to a "hold (c-)" rating in a report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $84.20.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.